Opiant Pharmaceuticals, Inc., CEO Roger Crystal, M.D., to Present to President's Commission on Combating Drug Addiction and t...
September 25 2017 - 7:00AM
Opiant Pharmaceuticals, Inc., (“Opiant”) (NASDAQ:OPNT), today
announced that Chief Executive Officer Roger Crystal, M.D., has
been invited to testify before the President's Commission on
Combating Drug Addiction and the Opioid Crisis and The Office of
National Drug Control Policy leadership. Dr. Crystal will present
to the commission, industry peers and meeting attendees regarding
his experience and perspective on Innovative Pain Management and
Prevention Measures for Diversion.
“I am honored to have been asked to represent
Opiant and outline the work we’re doing to address addiction in
America,” shared Roger Crystal, M.D., Chief Executive Officer of
Opiant. “This meeting represents an opportunity for industry
experts and advocates to come together to solve the drug epidemic
we face and to outline effective strategies to prevent similar,
addiction-based public health crises from debilitating future
generations.”
The meeting will be held on Wednesday, September
27, 2017, 12:30 – 2:30 PM EDT at the Eisenhower Executive Office
Building. The meeting will be livestreamed from the WhiteHouse.gov
website, and details of the meeting can be accessed on the Federal
Register’s Website.
Opiant collaborated with the National Institute
on Drug Abuse (NIDA) to develop NARCAN® Nasal Spray, the only
FDA-approved nasal naloxone, which is licensed to Adapt Pharma.
Opiant remains committed to further innovation and product
development in the addiction space. The company’s pipeline of nasal
opioid antagonists addresses both Alcohol Use and Eating Disorders.
Opiant is also developing additional therapies for Opioid Use
Disorder, including advancing the pre-clinical development of its
heroin vaccine candidate, which was licensed in October 2016 from
the Walter Reed Army Institute of Research and NIDA. Opiant
continues to maintain an active presence in national organizations
such as the National Institutes of Health (NIH), where Dr. Crystal
was recently invited to advise on the development of medications
for Opioid Use Disorder.
About Opiant Pharmaceuticals,
Inc.
Opiant Pharmaceuticals, Inc. is a specialty
pharmaceutical company developing pharmacological treatments for
addictions. NIDA, a division of the National Institutes of Health
(NIH), describes these disorders as chronic relapsing brain
diseases which burden society at both the individual and community
levels. With its innovative opioid antagonist nasal delivery
technology, Opiant is positioned to become a leader in these
treatment markets. Its first product, NARCAN, is approved for
marketing in the U.S. and Canada by the company’s partner, Adapt
Pharma Operations Limited. For more information please visit:
www.opiant.com.
Forward-Looking Statements
This press release contains forward-looking
statements. These statements relate to future events or our future
financial performance and involve known and unknown risks,
uncertainties and other factors that may cause our or our
industry’s actual results, levels of activity, performance or
achievements to be materially different from any future results,
levels of activity, performance or achievements expressed, implied
or inferred by these forward-looking statements. In some cases, you
can identify forward-looking statements by terminology such as
“may,” “will,” “should,” “could,” “would,” “expects,” “plans,”
“intends,” “anticipates,” “believes,” “estimates,” “predicts,”
“projects,” “potential,” or “continue” or the negative of such
terms and other comparable terminology. These statements are only
predictions based on our current expectations and projections about
future events. You should not place undue reliance on these
statements. Actual events or results may differ materially. In
evaluating these statements, you should specifically consider
various factors. These and other factors may cause our actual
results to differ materially from any forward-looking statement. We
undertake no obligation to update any of the forward-looking
statements after the date of this press release to conform those
statements to reflect the occurrence of unanticipated events,
except as required by applicable law.
CONTACT INFORMATION:
Corporate
Contact:Investor.relations@opiant.com
Media Contact:Casey MyburghKetchum Public
RelationsCasey.Myburgh@Ketchum.com202-835-8876
Investors:Sam MartinArgot
Partnerssam@argotpartners.com212-600-1902
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Apr 2023 to Apr 2024